Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Alcinous Pharmaceuticals logo — company profile

Alcinous Pharmaceuticals

Founded 2016 United States United States 1 employees Seed Total: $600.00K Biotechnology, Pharmaceutical

General Information

Company Name Alcinous Pharmaceuticals
Founded Year 2016
Location United States United States +1
Employees 1
Industries Biotechnology, Pharmaceutical
Funding Stage Seed
Social

Get notified when Alcinous Pharmaceuticals moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Alcinous Pharmaceuticals

Alcinous Pharmaceuticals is a biotechnology and pharmaceutical company, established in 2016 by three PhD students at the University of Rhode Island. The company is focused on creating therapeutics for aggressive cancers through a novel drug discovery pipeline. Their approach involves leveraging an innovative team to develop new classes of therapeutics.

In May 2020, the company secured a $600.00K investment in a Seed Round from Slater Technology Fund. With its headquarters in the United States, Alcinous Pharmaceuticals is poised to make significant strides in the field of cancer therapeutics.

Taxonomy: Therapeutics, Aggressive cancers, Drug discovery, Molecular design, Pharmaceuticals, Oncology, Pathologies, Protein targets, Innovation, Start-up, Research, University spin-off, PhD founded, Science-driven

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round •••••• 1
Investor
12 May 2020

Alcinous Pharmaceuticals Alternatives & Competitors

Alcinous Pharmaceuticals vs
BlueLight Therapeutics, Inc.
BlueLight Therapeutics, Inc. United States

BlueLight Therapeutics leverages a proprietary, structure-driven platform to develop new small molec...

Series C
2 employees
Biotechnology, Health Care
Alcinous Pharmaceuticals vs
EyeCyte
EyeCyte United States

Partnering with esteemed institutions to pioneer new treatments for retinal diseases.

Series A
1 employees
Biotechnology, Health Care
Alcinous Pharmaceuticals vs
PTM Therapeutics
PTM Therapeutics United States

Targeting Post Translational Modifications for Therapeutics Development

Series Unknown
2 employees
Health Care, Health and Wellness

FAQ About Alcinous Pharmaceuticals

We strive to design and develop therapeutics for aggressive cancers. Founded in 2016 by three PhD students at the University of Rhode Island, Alcinous Pharmaceuticals uses a novel drug discovery pipeline in tandem with their innovative team to develop new classes of therapeutics.
Alcinous Pharmaceuticals was founded in 2016.
Alcinous Pharmaceuticals is headquartered in United States.
Alcinous Pharmaceuticals operates in the following industries: Biotechnology, Pharmaceutical.
Alcinous Pharmaceuticals has approximately 1 employees.
Alcinous Pharmaceuticals has completed 1 funding round, raising a total of $600.00K. The latest funding stage is Seed.
Top alternatives and competitors to Alcinous Pharmaceuticals include BlueLight Therapeutics, Inc., EyeCyte, PTM Therapeutics, Trobix Bio, Revelation Biosciences Inc. . These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Alcinous Pharmaceuticals and BlueLight Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Alcinous Pharmaceuticals and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy